P=N/A, N=1178, Active, not recruiting, Biogen | Recruiting --> Active, not recruiting

P2, N=210, Not yet recruiting, Merry Life Biomedical Co., Ltd.

Notably, co-administration of brusatol abolished these effects, findings that are consistent with and strongly associated with Nrf2 activation; however, this mechanistic inference is based on pharmacologic inhibition. Collectively, ESA confers robust vascular protection against HCD-induced aortic remodeling and early atherosclerosis-like changes, with these effects being strongly associated with Nrf2 activation.

Additionally, high expression of NOX2 subunit genes and SNAI1 associated with reduced metastasis-free survival. These findings imply that myeloid cell-derived ROS initiate partial EMT in breast cancer cells to promote dissemination and that strategies to target myeloid cell-derived ROS may be explored to limit metastasis.

P1, N=70, Completed, Biogen | Recruiting --> Completed

P1, N=33, Active, not recruiting, Biogen | Trial primary completion date: Feb 2030 --> Sep 2025 | Recruiting --> Active, not recruiting

P=N/A, N=40, Recruiting, Centre Hospitalier Universitaire de Nice | Not yet recruiting --> Recruiting | Trial completion date: Oct 2025 --> Jun 2026 | Trial primary completion date: Sep 2025 --> Jun 2026

Lycorine can directly bind to and inhibit DPP3, thereby blocking the Nrf2 signaling pathway and downregulating SLC7A11. This disruption of GSH metabolism leads to the accumulation of ROS and iron overload, ultimately inducing ferroptosis in CRC cells.

Inhibition of p38 partially restored cell viability and reduced apoptosis. RTA-408 suppresses HCC cell survival through a p38-dependent stress response associated with NRF2 activation and LC3B/p62 accumulation.

P1, N=26, Recruiting, AnnJi Pharmaceutical Co., Ltd.

P2, N=192, Recruiting, University Hospital, Lille | Not yet recruiting --> Recruiting

P2/3, N=96, Recruiting, Nanjing Medical University